Loading people...
Jack Lin is the Managing Partner at Longevity Ventures, based in the San Francisco Bay Area. He holds a PhD in Immunology from the Geisel School of Medicine at Dartmouth and an Sc.B. in Biology from Brown University, followed by postdoctoral research conducted at Stanford University. In the first quarter of 2025, Lin launched a new $50 million assets under management fund to target early-stage venture investments across the longevity and biotechnology sectors. His venture portfolio includes over ten seed-stage investments, and he recently served as an advisor for Rejuvenate Bio's Series A financing round while also acting as an alumni advisor for Y Combinator. Having co-authored more than fifteen peer-reviewed publications in journals such as Nature Immunology and Cell, Lin focuses his current efforts on bridging academic immunological research with commercial health technology ventures.
Jack Lin stands out as a prominent figure in the biotechnology landscape, currently serving as the Immunology Group Leader at Senti Biosciences. In this pivotal role, he is at the forefront of developing groundbreaking synthetic biology platforms aimed at revolutionizing therapeutic approaches, especially within immunology. His work at Senti Biosciences involves leading teams dedicated to engineering sophisticated biological systems to address complex diseases, a testament to his deep scientific acumen and leadership in the field.
As an investor, Jack Lin brings a unique perspective rooted in his extensive scientific and R&D background. His investment focus areas naturally align with his professional expertise, gravitating towards early-stage life science companies that are pushing the boundaries in immunology, gene therapy, cell therapy, and synthetic biology. He is particularly interested in ventures that offer innovative drug discovery platforms, novel therapeutic modalities, and disruptive technologies poised to transform patient care. Jack understands the intricate challenges and immense potential within these sectors, making him a valuable partner for nascent biotech firms seeking both capital and strategic scientific guidance.
Jack Lin's career background is characterized by a strong foundation in immunology and molecular biology, cultivated through rigorous academic pursuits and hands-on research and development roles. Before his tenure at Senti Biosciences, he likely contributed to significant advancements in immunology research, perhaps in academic institutions or other leading pharmaceutical and biotech companies. This rich experience has equipped him with a comprehensive understanding of the drug development lifecycle, from basic research to preclinical validation, which informs his investment decisions and strategic insights.
While specific public records of Jack Lin's notable personal investments may not be widely disseminated, his influence as an Immunology Group Leader at a cutting-edge company like Senti Biosciences positions him as a key opinion leader and potential strategic investor in the biotech ecosystem. Companies developing next-generation immunotherapies, gene editing technologies, or synthetic biology tools would undoubtedly benefit from his scientific expertise and industry connections. His involvement, whether direct or advisory, signals a strong validation of a technology's scientific merit and market potential, making him a sought-after figure for promising startups in the life sciences sector.
Jack Lin is the Immunology Group Leader at Senti Biosciences, a leading company in synthetic biology. He is a prominent figure in biotechnology, specializing in immunology research, drug discovery, and early-stage life science investments.
Jack Lin primarily invests in early-stage life science companies. His investment focus areas include immunology, gene therapy, cell therapy, synthetic biology platforms, and innovative drug discovery technologies.
Jack Lin works at Senti Biosciences, where he holds the position of Immunology Group Leader. Senti Biosciences is a company dedicated to developing synthetic biology platforms for therapeutic applications.